森田　伸也 (モリタ　シンヤ)

Morita, Shinya

写真a

所属（所属キャンパス）

医学部 泌尿器科学教室 （信濃町）

職名

専任講師
このページの先頭へ▲

その他の所属・職名 【 表示 ／ 非表示 】

  • 医学部

このページの先頭へ▲

経歴 【 表示 ／ 非表示 】

  • 2009年04月
    -
    2011年03月

    荻窪病院

このページの先頭へ▲

学歴 【 表示 ／ 非表示 】

  • 　

    慶應義塾大学

このページの先頭へ▲

免許・資格 【 表示 ／ 非表示 】

  • 医師免許

このページの先頭へ▲
 

研究分野 【 表示 ／ 非表示 】

  • ライフサイエンス / 泌尿器科学

このページの先頭へ▲

研究キーワード 【 表示 ／ 非表示 】

  • 腎移植

このページの先頭へ▲
 

論文 【 表示 ／ 非表示 】

  • A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report

    Iwasawa T., Kosaka T., Morita S., Mikami S., Nakamura K., Hongo H., Nishihara H., Oya M.

    BMC Medical Genomics （BMC Medical Genomics)  15 （ 1 ）  2022年12月

    　概要を見る

    Background: Abnormalities in homologous recombination contribute to the aggressive nature of castration-resistant prostate cancer. Retinoblastoma transcriptional corepressor 1 (RB1) and breast cancer 2 (BRCA2) exist close to each other in the same chromosome, and the significance of their concurrent loss has become a hot topic in the field of cancer research. Case presentation: A 61-year-old man presented with a chief complaint of a mass on his head and was diagnosed as multiple bone metastases from prostate cancer. He was treated with standard medication, but he died 2 years 6 months after being diagnosed with prostate cancer. Simultaneous biallelic loss of RB1 and BRCA2 as well as a truncating mutation of tumor protein p53 (TP53) were revealed by genomic analysis. Conclusion: To our knowledge, this is the first report of castration-resistant prostate cancer (CRPC) with BRCA2 and RB1 co-loss and TP53 mutation. To establish a treatment strategy for highly malignant cases with such multiple genetic features is important.

  • Endoscopic vaporization of benign prostatic hyperplasia using a contact 980 nm diode laser under antithrombotic therapy: A prospective survey

    Sanjo T., Tanaka N., Shinojima T., Yasumizu Y., Takeda T., Matsumoto K., Morita S., Kosaka T., Mizuno R., Asanuma H., Oya M.

    Asian journal of endoscopic surgery （Asian journal of endoscopic surgery)  15 （ 3 ） 585 - 590 2022年07月

    　概要を見る

    INTRODUCTION: To prospectively clarify whether endoscopic contact laser vaporization of the prostate (CVP) can be safely performed even in patients undergoing antithrombotic therapy. METHODS: Fifty-five patients treated with CVP were enrolled. Patients were assigned to: (i) the antithrombotic therapy group (n = 21, 38%); or (ii) control group without antithrombotic therapy (n = 34, 62%). All patients in the antithrombotic therapy group continued all antithrombotic agents during the perioperative period and thereafter. RESULTS: No difference was noted in patient background between the two groups. In primary endpoints, decreases in the postoperative hemoglobin level were remarkable in the antithrombotic therapy group, while no serious effects were noted in either group. The control and antithrombotic therapy groups did not show a significant difference in the occurrence of catheter obstruction due to blood clots or serious hematuria following catheter removal. During follow-up, transurethral coagulation for hemostasis was needed only in the antithrombotic therapy group, with a frequency of transurethral coagulation of up to 14%. In secondary endpoints, no difference in the occurrence of perioperative or late-onset complications after surgery was noted between the two groups. Finally, no difference was noted in improvements in the International Prostate Symptom Score (IPSS), IPSS quality of life score, overactive bladder symptom score, maximum flow rate, or post-voiding residual urine volume between the two groups throughout the follow-up period. CONCLUSIONS: CVP can be performed safely and effectively in patients undergoing continuous antithrombotic therapy. However, the possibility of secondary bleeding after discharge in a subset of patients, such as those undergoing antithrombotic therapy, may be noted.

  • Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy

    Mizuno R., Takamatsu K., Yasumizu Y., Tanaka N., Takeda T., Morita S., Matsumoto K., Kosaka T., Asanuma H., Mikami S., Oya M.

    Urologia Internationalis （Urologia Internationalis)  106 （ 11 ） 1145 - 1149 2022年

    ISSN  00421138

    　概要を見る

    Introduction: The aim of this retrospective study was to elucidate predictors of survival in metastatic renal cell carcinoma (mRCC) patients in an International Metastatic Renal Cell Carcinoma Database Consortium favorable risk group treated with frontline therapy without immune checkpoint inhibitors. Methods: A total of 238 patients with mRCC were reviewed. Among them, 55 patients in favorable risk group treated with single-agent systemic therapy were retrospectively analyzed. Clinical and pathological data were retrieved and analyzed retrospectively. The prognostic effect of each marker on overall survival (OS) was investigated with univariate and multivariate Cox's proportional hazards regression models. Results: After a median follow-up of 46.2 months after first-line treatment initiation, the median progression-free survival (PFS) was 29.3 months, and the median OS has not been reached. The estimated percentage of patients who were alive at 12 and 24 months were 96.1 and 94.1%, respectively. Multivariate analysis revealed that the long-term duration of first-line treatment (hazard ratio [HR]: 0.972, 95% confidence interval [CI]: 0.944-0.997, p = 0.0299) and the metastases limited to lung (HR: 3.852, 95% CI: 1.080-24.502, p = 0.0361) were independent predictors for longer OS in favorable risk mRCC patients. Conclusion: First-line systemic therapy for favorable risk mRCC patients with a single agent resulted in relatively longer PFS and OS. A longer duration of first-line treatment and lung only metastases are correlated with longer OS.

  • Predictors of renal function after adrenalectomy in patients with Cushing or subclinical Cushing syndrome

    Kufukihara R., Takeda T., Hakozaki K., Yasumizu Y., Tanaka N., Matsumoto K., Morita S., Kosaka T., Mizuno R., Asanuma H., Miyashita K., Kurihara I., Oya M.

    International Journal of Urology （International Journal of Urology)  2022年

    ISSN  09198172

    　概要を見る

    Purpose: The postoperative course of renal function remains unclear in Cushing syndrome. We examined changes in renal function after adrenalectomy in patients with Cushing syndrome and attempted to identify predictors of renal impairment. Methods: The study population comprised 76 patients who underwent adrenalectomy for Cushing and subclinical Cushing syndrome between 2001 and 2018. Renal function and other factors were evaluated pre-operation, at 1 postoperative month, and 1 postoperative year. We defined a ≥10% decrease in the estimated glomerular filtration rate at 1 postoperative year as renal impairment, and predictors associated with this reduction were investigated. The relationship between renal function and steroid replacement after surgery was also examined. Results: Mean pre-operative estimated glomerular filtration rate was 82.2 ml/min/1.73 m2. While mean estimated glomerular filtration rate was significantly lower at 1 postoperative month than the pre-operative value (71.7 ml/min/1.73 m2 [89.1%], p < 0.001), no significant differences were observed between 1 postoperative year and pre-operation (79.5 ml/min/1.73 m2 [97.6%], p = 0.108). Twenty-six patients (34.2%) developed renal impairment. A multivariate analysis identified a low pre-operative adrenocorticotropic hormone level as an independent predictor of renal impairment (odds ratio 6.30, p = 0.031). Among 43 patients with available records of steroid replacement history, 18 (41.9%) developed renal impairment. The ratio of patients with a reduced steroid replacement dose at 1 postoperative month was significantly lower among patients with renal impairment than those without (22.2% vs. 56.0%, p = 0.027). Conclusions: The pre-operative adrenocorticotropic hormone level was a predictor of renal function after adrenalectomy in patients with Cushing or subclinical Cushing syndrome.

  • Hybridisation chain reaction-based visualisation and screening for lncRNA profiles in clear-cell renal-cell carcinoma

    Kufukihara R., Tanaka N., Takamatsu K., Niwa N., Fukumoto K., Yasumizu Y., Takeda T., Matsumoto K., Morita S., Kosaka T., Aimono E., Nishihara H., Mizuno R., Oya M.

    British Journal of Cancer （British Journal of Cancer)  2022年

    ISSN  00070920

    　概要を見る

    Background: Analysis of long noncoding RNA (lncRNA) localisation at both the tissue and subcellular levels can provide important insights into the cell types that are important for their function. Methods: By applying new fluorescent in situ hybridisation technique called hybridisation chain reaction (HCR), we achieved a high-throughput lncRNA visualisation and evaluation of clinical samples. Results: Assessing 1728 pairs of 16 lncRNAs and clear-cell renal-cell carcinoma (ccRCC) specimens, three lncRNAs (TUG1, HOTAIR and CDKN2B-AS1) were associated with ccRCC prognosis. Furthermore, we derived a new lncRNA risk group of ccRCC prognosis by combining the expression levels of these three lncRNAs. Examining genomic alterations underlying this classification revealed prominent features of tumours that could serve as potential biomarkers for targeting lncRNAs. We then derived combination of HCR with expansion microscopy and visualised nanoscale-resolution HCR signals in cell nuclei, uncovering intracellular colocalization of three lncRNA (TUG1, HOTAIR and CDKN2B-AS1) signals such as those located intra- or out of the nucleus or nucleolus in cancer cells. Conclusion: LncRNAs are expected to be desirable noncoding targets for cancer diagnosis or treatments. HCR involves plural probes consisting of small DNA oligonucleotides, clinically enabling us to detect cancerous lncRNA signals simply and rapidly at a lower cost.

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

  • 挙児希望を主訴とした成人発症特発性低ゴナドトロピン男性子性腺機能低下症の2例

    大橋 正和, 松島 将史, 野中 昭一, 片岡 典子, 宇都 博文, 杉山 武, 吉田 宏之, 佐藤 卓, 森田 伸也, 高松 公晴

    日本生殖医学会雑誌 ((一社)日本生殖医学会)  67 ( 4 ) 347 - 347 2022年10月

    ISSN  1881-0098

  • 接触式レーザー前立腺蒸散術の治療成績　後出血を来した症例の検討

    田中 伸之, 三條 丹星, 安水 洋太, 武田 利和, 松本 一宏, 森田 伸也, 小坂 威雄, 水野 隆一, 浅沼 宏, 大家 基嗣

    日本排尿機能学会誌 ((一社)日本排尿機能学会)  33 ( 1 ) 299 - 299 2022年09月

    ISSN  1347-6513

  • バイオインフォマティクスを用いたカバジタキセル耐性前立腺癌リプログラミング薬剤のスクリーニング

    本郷 周, 小坂 威雄, 安水 洋太, 田中 伸之, 武田 利和, 森田 伸也, 松本 一宏, 水野 隆一, 大家 基嗣

    泌尿器外科 (医学図書出版(株))  35 ( 8 ) 866 - 866 2022年08月

    ISSN  0914-6180

  • 膀胱メラノーシスの1例

    渡邊 雅斗, 田中 伸之, 岩澤 智裕, 安水 洋太, 武田 利和, 森田 伸也, 松本 一宏, 小坂 威雄, 秋田 大宇, 上野 彰久, 新井 恵吏, 水野 隆一, 浅沼 宏, 陣崎 雅弘, 大家 基嗣

    泌尿器外科 (医学図書出版(株))  35 ( 7 ) 640 - 640 2022年07月

    ISSN  0914-6180

  • 副腎性クッシング症候群における術後腎機能推移の検討

    久冨木原 良平, 武田 利和, 箱崎 恭平, 安水 洋太, 田中 伸之, 松本 一宏, 森田 伸也, 小坂 威雄, 水野 隆一, 栗原 勲, 浅沼 宏, 伊藤 裕, 大家 基嗣

    泌尿器外科 (医学図書出版(株))  35 ( 臨増 ) 821 - 821 2022年07月

    ISSN  0914-6180

全件表示 >>

このページの先頭へ▲

研究発表 【 表示 ／ 非表示 】

  • 診断が困難であった前立腺肉腫の1例

    金子　剛、石田　勝、山崎恵一、森田伸也、越田竹朗、西本紘嗣郎、中島　淳、村井　勝、亀山香織、向井萬起男

    日本泌尿器科学会東京地方会 (東京) , 

    2006年07月
    , 

    口頭発表（一般）

  • ABO不適合生体腎移植後にCMVアンチゲネミア陽性をきたした2例

    香野日高、中川健、森田伸也、宮島哲、朝倉博孝、中島淳、村井勝

    第39回臨床腎移植学会 (鬼怒川) , 

    2006年01月
    , 

    口頭発表（一般）

  • 糖尿病性腎症による腎不全に対する高齢者腎移植の1例

    森田伸也、中川健、宮島哲、村井勝

    第39回臨床腎移植学会 (鬼怒川) , 

    2006年01月
    , 

    口頭発表（一般）

  • 後腹膜腔に発生し，膀胱の著明な圧迫を来した偽粘液腫の1例

    森田伸也，香野日高，篠島利明，大東貴志，村井勝

    第555回日本泌尿器科学会東京地方会 (東京) , 

    2002年07月
    , 

    口頭発表（一般）

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • 移植腎長期生着へ向けた慢性移植腎症非免疫学的メカニズムの解明と予防法の開発

    2019年04月
    -
    2022年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 森田　伸也, 基盤研究（Ｃ）, 補助金,  研究代表者

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 泌尿器科学講義

    2024年度

  • 泌尿器科学講義

    2023年度

  • 泌尿器科学講義

    2022年度

  • 泌尿器科学講義

    2021年度

  • 泌尿器科学講義

    2020年度

全件表示 >>

このページの先頭へ▲